+7 (701) 759 90 19
USD 424.99 EUR 504.21
RUB 5.81 CNY 65.66
News

3rd stage of clinical trials of QazCovid-in vaccine to be 50% complete by Apr 15

9 April 2021 11:08
Share in:
3rd stage of clinical trials of QazCovid-in vaccine to be 50% complete by Apr 15

KORDAI. KAZINFORM – The third stage of clinical trials of Kazakhstan’s homegrown vaccine QazCovid-in will be 50% complete by April 15, Director General of the Research Institute for Biological Safety Problems Kunsulu Zakarya said Friday, Kazinform correspondent reports.

Related news
New batch of Chinese COVID-19 vaccines arrives in Iran S. Korea: New cases stay in 1,200s for 2nd day, no signs of letup amid 4th wave of pandemic Nur-Sultan’s COVID-19 cases remain stable despite fast-spreading Delta variant

In her words, in order to be used for medical purposes, every vaccine has to be put to several rounds of tests. That includes pre-clinical trials on animals and then several stages of clinical trials.

Kunsulu Zakarya revealed that QazCovid-in had 100% efficacy in the first stage of clinical trials and 96% efficacy in the second stage of clinical trials. The third stage of clinical trials is set to be 50% complete by April 15. Only after that the experts of the Institute will be able to reveal the efficacy of the homegrown vaccine in the third stage.

She also said that given the complicated epidemiological situation and urgent need in vaccines, many countries start using vaccines after the second or in the middle of the third stages of clinical trials.

Earlier it was revealed that the first 50,000 doses of the QazCovid-in vaccine will become available in late April. The Research Institute for Biological Safety Problems and SK Pharmacy agreed to supply 2 million doses of Kazakhstan’s vaccine which will be branded as QazVac in the market.



Share in:

Author:

Kudrenok Tatyana

Related news
Read also
+7
Send
Employees online
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048

Archive